Author:
Simonson Andrew W.,Zeppa Joseph J.,Bucsan Allison N.,Chao Michael C.,Pokkali Supriya,Hopkins Forrest,Chase Michael R.,Vickers Andrew J.,Sutton Matthew S.,Winchell Caylin G.,Myers Amy J.,Ameel Cassaundra L.,Kelly Ryan,Krouse Ben,Hood Luke E.,Li Jiaxiang,Lehman Chelsea C.,Kamath Megha,Tomko Jaime,Rodgers Mark A.,Donlan Rachel,Chishti Harris,Borish H. Jacob,Klein Edwin,Scanga Charles A.,Fortune Sarah,Lin Philana Ling,Maiello Pauline,Roederer Mario,Darrah Patricia A.,Seder Robert A.,Flynn JoAnne L.
Abstract
AbstractTuberculosis (TB) is a major cause of morbidity and mortality worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the route and dose of BCG vaccination from 5ξ105CFU ID to 5ξ107CFU intravenous (IV) resulted in prevention of infection and disease in a rigorous, highly susceptible non-human primate model of TB. Identifying the immune mechanisms of protection for IV BCG will facilitate development of more effective vaccines against TB. Here, we depleted select lymphocyte subsets in IV BCG vaccinated macaques prior to Mtb challenge to determine the cell types necessary for that protection. Depletion of CD4 T cells or all CD8α expressing lymphoycytes (both innate and adaptive) resulted in loss of protection in most macaques, concomitant with increased bacterial burdens (∼4-5 log10 thoracic CFU) and dissemination of infection. In contrast, depletion of only adaptive CD8αβ+ T cells did not significantly reduce protection against disease. Our results demonstrate that CD4 T cells and innate CD8α+ lymphocytes are critical for IV BCG-induced protection, supporting investigation of how eliciting these cells and their functions can improve future TB vaccines.One Sentence SummaryAntibody depletion of lymphocytes in rhesus macques demonstrates key roles for CD4 T cells and innate-like CD8α+ lymphocytes in conferring sterilizing immunity against tuberculosis following intravenous BCG vaccination.
Publisher
Cold Spring Harbor Laboratory
Reference67 articles.
1. W. H. Organization, Global Tuberculosis Report. (2023).
2. “Mitigating the Impact of COVID-19 on Countries Affected by HIV, Tuberculosis and Malaria.,” (The Global Fund, 2020).
3. “The Potential Impact of the COVID-19 Response on Tuberculosis in High-Burden Countries: A Modelling Analysis.,” (Stop TB Partnership, 2020).
4. G. B. Migliori , D. Dowdy , J. T. Denholm , L. D’Ambrosio , R. Centis , The path to tuberculosis elimination: a renewed vision. European Respiratory Journal 61, 2300499 (2023).
5. G. Voss et al., Progress and challenges in TB vaccine development. F1000Research 7, (2018).